Skip to main content

Web Exclusives

Ovarian Cancer

Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer

Ovarian Cancer, PARP Inhibitors

PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile

Ovarian Cancer

Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib

Lung Cancer, FDA Updates

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

FDA Updates

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

Lung Cancer, FDA Updates

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

Ovarian Cancer

Zejula Receives New Indication as Maintenance Treatment for Patients with Advanced Ovarian Cancer

Ovarian Cancer

Improving Patient Access to Biologics: Q&A with Melissa Paige (Part 2 of 2)

Ovarian Cancer

CMS Covers Telehealth During Emergency Declaration

Ovarian Cancer

Remote Patient Monitoring Is on the Upswing, with Promising Outcomes Data

Page 13 of 43
Results 121 - 130 of 425